Empagliflozin-Pirfenidone Dual Therapy in a Rat HFpEF Model

16 rats per group were used in a preclinical study evaluating the synergistic effects of empagliflozin and pirfenidone on heart failure with preserved ejection fraction. The dataset includes results from echocardiography, histopathology, exercise tolerance testing, RNA sequencing, and Western blotting. The research was authored by Yuexin Yu and last updated in June 2026.

Use Cases

• Analyze synergistic drug effects based on echocardiography and histopathology results described in the study
• Investigate transcriptomic mechanisms based on RNA sequencing data mentioned in the description
• Model pharmacological synergy based on the Bliss independence analysis method used
• Study fibrosis and hypertrophy reversal based on histological findings of reduced collagen deposition and cellular hypertrophy

Strengths

• Data is derived from a controlled preclinical study with 16 rats per group, allowing for statistical comparison.
• Analysis includes multiple modalities: echocardiography, histopathology, exercise testing, and transcriptomics.
• The dataset is associated with a detailed research methodology described in the document.

Limitations

• The dataset is a 3.0 MB DOCX file; the underlying raw numerical or image data may not be directly accessible.
• Row count and column-level documentation are unknown, which limits suitability assessment for direct computational analysis.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

Yuexin Yu

Collection Method

Data was generated from a preclinical animal study inducing HFpEF in Sprague-Dawley rats using a two-hit model (L-NAME and high-fat diet) over 5 weeks, followed by 4 weeks of drug treatment.

Freshness

Last updated 2026-06-03 06:01:23; freshness should be verified.